The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SOURCE: Prediction models for overall survival in patients with metastatic and potentially curable esophageal and gastric cancer.
 
Héctor G. van den Boorn
No Relationships to Disclose
 
Ameen Abu-Hanna
Consulting or Advisory Role - ExpertDoc; ExpertDoc; ExpertDoc; ExpertDoc
 
Nadia Haj Mohammad
Consulting or Advisory Role - BMS Brazil; BMS Brazil; BMS Brazil; BMS Brazil; Celgene; Celgene; Celgene; Celgene; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD
Research Funding - SERVIER; SERVIER; SERVIER; SERVIER
Travel, Accommodations, Expenses - BMS Brazil; BMS Brazil; BMS Brazil; BMS Brazil
 
Maarten C.C.M. Hulshof
No Relationships to Disclose
 
Suzanne S. Gisbertz
No Relationships to Disclose
 
Bastiaan R. Klarenbeek
No Relationships to Disclose
 
Marije Slingerland
No Relationships to Disclose
 
Laurens Victor Beerepoot
No Relationships to Disclose
 
Tom Rozema
No Relationships to Disclose
 
Mirjam A.G. Sprangers
No Relationships to Disclose
 
Rob H. A. Verhoeven
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
 
Aeilko H. Zwinderman
No Relationships to Disclose
 
Martijn G.H. van Oijen
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Nordic Bioscience (Inst); Nordic Bioscience (Inst); Nordic Bioscience (Inst); Nordic Bioscience (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst)
 
Hanneke W.M. Van Laarhoven
Honoraria - Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Lilly/ImClone; Nordic Group; Nordic Group; Nordic Group; Nordic Group; Servier; Servier; Servier; Servier
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Janssen-Cilag (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Philips Healthcare (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Servier (Inst); Servier (Inst); Servier (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca